Processing Magazine

Onyx Pharmaceuticals considers sale

November 29, 2011

SAN FRANCISCO — Onyx Pharmaceuticals Inc., known for its kidney-cancer treatment Nexavar, is exploring options, including a possible sale, according to Bloomberg.

Potential buyers are studying Onyx''s business and its experimental carfilzomib cancer therapy.

Onyx had a market value of about $2.4 billion as of Nov. 25 and is working with Centerview Partners LLP to review alternatives, the article stated.